US 10052386
Progesterone formulations
granted A61KA61K31/565A61K31/566
Quick answer
US patent 10052386 (Progesterone formulations) held by Compass Therapeutics LLC expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Compass Therapeutics LLC
- Grant date
- Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 40
- CPC classes
- A61K, A61K31/565, A61K31/566, A61K31/57, A61K31/573